GlassScriptPhysician profile
Robert J Wong
NPI 1952625147
$50,849.23
in general payments reported to CMS, 2019-2025
10 companies · $1,200 in 2025
The $1,200 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $4,789 · 2021: $3,040 · 2022: $3,500 · 2023: $2,465 · 2024: $1,343 · 2025: $1,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,743 · Food and Beverage: $197 · Education: $67.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,742.50 |
| Food and Beverage | $197.00 |
| Education | $67.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $41,958.18 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,500.00 | 2022 | |
| Siemens Medical Solutions USA, INC. | $2,397.00 | 2023 | |
| Glaxosmithkline, LLC. | $1,440.00 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,102.50 | 2024 | |
| Abbvie INC. | $147.82 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $122.90 | 2019 | |
| Dova Pharmaceuticals | $113.18 | 2019 | |
| Mallinckrodt Hospital Products INC. | $67.65 | 2023 | Terlivaz |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.